NCMP-13. BDNF ENHANCEMENT VIA AMPAKINES AS A POTENTIAL TREATMENT FOR CHEMOTHERAPY-RELATED COGNITIVE IMPAIRMENT
Abstract OBJECTIVES: Chemotherapy-related cognitive impairment (CRCI) is widely reported among cancer survivors. We focus on the neurocognitive impairments provoked by cisplatin, which is used for treatment of various malignancies including ovarian, testicular, head and neck cancers, and pediatric brain tumors. More than 30% of advanced ovarian cancer patients develop CRCI during and after cisplatin-based chemotherapy. We examined the role of brain-derived neurotrophic factor (BDNF) downregulation in cisplatin-induced CRCI, and whether pharmacological BDNF augmentation via ampakines can prevent cisplatin-induced neuronal damage. BDNF is broadly expressed in the hippocampus where it regulates dendritic spine integrity and neurogenesis, among other functions.